Skip to main content

Table 5 FNA performance per cytology group

From: The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes

Performance on SFM (n = 12)
Genetic alteration Histology malignant (n = 11) Histology benign (n = 1)
Positive 4 0
Negative 7 1
  1. Sensitivity, 36 % (11–69); Specificity, 100 % (3–100); PPV, 92 % (76–98); NPV, 9 % (4–17), prevalence of malignant lesions, 92 %. Estimated performance when malignancy is prevalent at 24 %: PPV, 25 % (8–53); NPV, 77 % (58–88). Estimated performance when malignancy is prevalent at 62 %: PPV, 64 % (32–85); NPV, 39 % (21–59)